• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract:Adjuvant radiotherapy does not improve survival following prostatectomy in men with localized or locally advanced prostate cancer

byConstance Wu
November 12, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. There is no evidence that adjuvant radiotherapy improves survival compared with early salvage radiotherapy following radical prostatectomy with localized or locally advanced prostate cancer.

2. Pre-surgical PSA, Gleason score, seminal vesicle involvement and surgical margins did not influence the effect of adjuvant radiotherapy on event-free survival.

Evidence Rating Level: 1 (Excellent)

Study Rundown: There is a lack of consensus in current guidelines on whether adjuvant or early salvage radiotherapy is more appropriate following prostatectomy in patients with localized or locally advanced prostate cancer. Prior randomized trials have showed adjuvant radiotherapy to result in better biochemical control compared to observation but did not show a consistent benefit for long-term survival outcomes. Thus, the recommendation of adjuvant radiotherapy in clinical practice has been questioned. This systematic review and meta-analysis utilized a prospective framework for adaptive meta-analysis (FAME) to include three randomized controlled trials comparing immediate adjuvant radiotherapy versus early salvage radiotherapy men following radical prostatectomy with localized or locally advanced prostate cancer. Results showed no evidence that use of adjuvant radiotherapy following prostatectomy improved PSA-driven event-free survival in men with prostate cancer. Additionally, there was no evidence that the effectiveness of adjuvant radiotherapy varied based on pre-surgical PSA, Gleason score, seminal vesicle involvement or surgical margins. A notable strength of the study includes the utilization of a prospective FAME approach to work closely with trialists to limit bias both in study selection and in the analysis through harmonizing key survival outcome definitions and allowed for the planning of analysis prior to the final trial results being known. The absence of individual participant data during the study period necessitated the adoption of an aggregate data approach and therefore insufficient power to detect a very small (<5%) benefit of early radiotherapy.

Click to read the study in The Lancet

Relevant Reading: Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension

In-Depth [systematic review]: This systematic review and meta-analysis of aggregate data utilized a prospective framework for adaptive meta-analysis (FAME) approach to include three ongoing trials recruiting men (age >18 years) with localized or locally advanced prostate cancer who had radical prostatectomy prior to trial enrolment. Trials included were aimed to compare adjuvant radiotherapy to a policy of deferred, early salvage radiotherapy following radical prostatectomy. The primary outcome measure at this initial stage of the meta-analysis was event-free survival with all included trials utilized a harmonized definition of this outcome with identical endpoints.

RELATED REPORTS

Active monitoring, prostatectomy, and radiotherapy as treatment options for localized prostate cancer result in similar prostate-cancer-mortality

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Wellness Check: Nutrition

A total of 2153 patients (median age 64-65 years; 1075 randomized to receive adjuvant radiotherapy)) were included in the aggregate data analysis with median follow-up ranging from 60 to 78 months. Most patients had a Gleason score of 7 (1671 patients, 77.6%), positive surgical margins (1526 patients, 70.9%), either stage pT3a or b disease (1719 patients, 79.8%) and extracapsular extension (1656 patients, 76.9%). Of the 270 events recorded, there was no evidence that event-free survival was significantly improved with adjuvant radiotherapy compared to early salvage radiotherapy (hazard ratio (HR) 0.95, 95% CI 0.75 to 1.21; p=0.70) with results being consistent across trials (heterogeneity p=0.18 I2=42%). The baseline event-free survival rate was 88% at 5 years with a 1% absolute difference between early salvage radiotherapy and adjuvant radiotherapy (95% CI -2 to 3). There was no evidence that event-free survival following adjuvant radiotherapy varied based on predefined subgroups including pre-surgical PSA, Gleason score, seminal vesicle involvement or surgical margins.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant radiotherapyearly salvage therapygleason scoreprostate cancerprostatectomy
Previous Post

Elevated plasma ACE2 associated with an increased risk of poor cardiovascular outcomes

Next Post

Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis

RelatedReports

Oncology

Active monitoring, prostatectomy, and radiotherapy as treatment options for localized prostate cancer result in similar prostate-cancer-mortality

March 20, 2023
Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer
StudyGraphics

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

January 4, 2023
Next Post
Elective colectomy associated with improved survival in ulcerative colitis

Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis

Parental nonmedical prescription opioid use linked to adolescent use

Association between antipsychotic use and ischemic heart disease found in women

Parents often unaware of adolescents’ suicidal thoughts

Inflammatory markers associated with depressive symptoms and suicidality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options